#Role of Genomics in Drug Repurposing

[scichores]

Fascinating Role of Genomics in Drug Discovery and Development

This article dives deep into the significance of genomics in drug discovery and development, highlighting well-known genomic-based drug development services that are driving the future of pharmaceutical therapies. #genomics #drugdiscovery

A scientist using a whole genome DNA sequencer, in order to determine the “DNA fingerprint” of a specific bacterium. Original image sourced from US Government department: Public Health Image Library, Centers for Disease Control and Prevention. Under US law this image is copyright free, please credit the government department whenever you can”. by Centers for Disease Control and Prevention is…

[kayvanh123]

Discovery of new genetic links offers potential for the prevention and treatment of a common form of inflammatory arthritis.

A groundbreaking genetic study has identified two key genes linked to calcium pyrophosphate deposition (CPPD) disease, a painful and common form of inflammatory arthritis also known as pseudogout. Published in the Annals of the Rheumatic Diseases, this first-ever genome-wide association study (GWAS) highlights ENPP1 and RNF144B as major contributors to the development of CPPD in people of both European and African ancestry.

What Is CPPD Disease?

Calcium pyrophosphate deposition disease (CPPD) is a type of crystal-induced arthritis caused by the buildup of calcium pyrophosphate crystals in the joints. Often mistaken for gout, pseudogout leads to episodes of severe joint pain, inflammation, and swelling. CPPD is most common in adults over 60 and is seen in up to 30% of people over the age of 80.

In many cases, CPPD also coexists with osteoarthritis, and while the connection is not fully understood, the condition contributes significantly to joint damage and reduced mobility in older adults.

Key Findings: ENPP1 and RNF144B Identified as Genetic Drivers of CPPD

This large-scale genetic study was conducted through the Million Veteran Program, which includes health data from over 550,000 U.S. Veterans. Researchers analyzed every gene in the human genome to uncover genetic links to CPPD arthritis, and the results were clear: ENPP1 and RNF144B are strongly associated with the disease across multiple ethnic groups.

ENPP1 encodes a protein responsible for producing inorganic pyrophosphate, a critical component in CPP crystal formation.

RNF144B, though less understood, appears to play a role in inflammatory signaling pathways relevant to arthritis.

A Major Breakthrough in Understanding and Treating Pseudogout

Dr. Tony R. Merriman, lead researcher from the University of Alabama at Birmingham and University of Otago, explains:“Our discovery of ENPP1 is a game-changer. This gene directly impacts the chemical pathways that lead to CPP crystal buildup. It provides a clear and actionable target for new therapies.”

Dr. Sara K. Tedeschi, a rheumatologist at Harvard Medical School, adds:“This is an exciting time. ENPP1 inhibitors, already under development for other diseases, could be repurposed to finally offer an effective treatment for CPPD disease—something patients have needed for decades.”

Why This Study Matters: Unmet Need for CPPD Treatment

Currently, CPPD disease treatment options are limited to managing inflammation with NSAIDs, colchicine, or corticosteroids. There are no therapies that target the root cause—crystal formation.

Dr. Josef Smolen, Editor-in-Chief of Annals of the Rheumatic Diseases, emphasizes:“This landmark GWAS not only identifies potential drug targets but also brings us closer to precision medicine for inflammatory arthritis like pseudogout.”

What’s Next?

Because ENPP1 inhibitors are already in development for cancer and infectious diseases, they may soon be tested in clinical trials for CPPD arthritis. This could rapidly accelerate the timeline for delivering effective, disease-modifying treatments.

Key Takeaways for Patients and Healthcare Providers

CPPD (pseudogout) is a common inflammatory arthritis in older adults caused by calcium pyrophosphate crystals.

New genetic research identifies ENPP1 and RNF144B as key contributors.

ENPP1 inhibitors may represent a future treatment for CPPD disease.

Current CPPD treatments only manage symptoms, not the underlying cause.

If you or someone you know suffers from pseudogout or unexplained joint pain, stay informed about new genetic research and treatment options. Subscribe to our newsletter for the latest updates on CPPD disease and arthritis breakthroughs.

For more information about our clinic, medical professionals, and treatment options, please visit our main website.

[anviduby]

Atopic Dermatitis Market Intelligence: The Role of Artificial Intelligence in Drug Discovery and Diagnosis

Introduction

The Atopic dermatitis market is a chronic inflammatory skin condition that significantly impacts patients' quality of life. Recent advancements in artificial intelligence (AI) have revolutionized both the diagnosis and treatment of AD. AI's ability to analyze vast datasets and identify patterns has accelerated drug discovery processes and enhanced diagnostic accuracy, offering promising avenues for personalized medicine.

AI in Drug Discovery for Atopic Dermatitis

AI technologies have transformed the landscape of drug discovery, particularly in the realm of AD. Traditional drug development is often time-consuming and costly, but AI has introduced more efficient methodologies.

Target Identification and Validation: AI algorithms analyze genomic, proteomic, and clinical data to identify potential therapeutic targets for AD. For instance, Insilico Medicine utilizes AI to predict the efficacy of compounds against specific targets, expediting the identification of promising drug candidates .

Drug Repurposing: AI facilitates the repurposing of existing drugs for AD treatment by analyzing existing databases to find new therapeutic indications. This approach can significantly reduce development time and costs.

Predictive Modeling: Machine learning models predict the pharmacokinetics and toxicity profiles of drug candidates, aiding in the selection of the most promising compounds for clinical trials.

Clinical Trial Optimization: AI assists in designing more efficient clinical trials by identifying suitable patient populations and predicting potential outcomes, thereby enhancing the likelihood of trial success.

AI in Diagnosis and Monitoring of Atopic Dermatitis

AI's impact extends beyond drug discovery into the realm of diagnosis and monitoring of AD.

Image Recognition: AI-powered systems analyze skin lesion images to diagnose AD with high accuracy. For example, convolutional neural networks (CNNs) have been trained on large datasets of skin images to identify characteristic patterns of AD lesions .

Severity Assessment: AI models assess the severity of AD by analyzing clinical images and patient-reported symptoms. This objective assessment aids clinicians in determining appropriate treatment plans.

Wearable Technology: AI-integrated wearable devices monitor patients' scratching behaviors, providing real-time data on disease activity. Studies have shown that accelerometer-equipped wristwatches can detect scratching motions with high accuracy, offering insights into disease progression .

Predictive Analytics: AI analyzes patient data to predict flare-ups and disease progression, enabling proactive management and personalized treatment strategies.

Challenges and Ethical Considerations

Despite the promising applications of AI in AD, several challenges and ethical considerations must be addressed.

Data Privacy: The use of patient data in AI models raises concerns about data privacy and security. Ensuring that patient information is anonymized and securely stored is paramount.

Bias and Generalization: AI models trained on specific populations may not generalize well to diverse patient groups. It's crucial to ensure that AI systems are trained on diverse datasets to avoid biases in diagnosis and treatment recommendations.

Regulatory Approval: The integration of AI into clinical practice requires regulatory approval. Establishing clear guidelines and standards for AI applications in healthcare is essential to ensure safety and efficacy.

Clinical Integration: Incorporating AI tools into existing clinical workflows requires training healthcare professionals and adapting infrastructure to support AI technologies.

Future Outlook

The future of AD management lies in the integration of AI with personalized medicine approaches.

Precision Medicine: AI enables the analysis of individual patient data to tailor treatment plans, optimizing therapeutic outcomes.

Biomarker Discovery: AI aids in identifying biomarkers associated with AD, facilitating early diagnosis and personalized treatment strategies.

Patient Empowerment: AI-powered mobile applications and wearable devices empower patients to monitor their condition and engage actively in their treatment plans.

Global Health Impact: AI has the potential to improve access to AD diagnosis and treatment in underserved regions by providing remote diagnostic capabilities and personalized care recommendations.

Conclusion

Artificial intelligence is reshaping the landscape of atopic dermatitis management by enhancing drug discovery processes and improving diagnostic accuracy. While challenges exist, the integration of AI into clinical practice holds the promise of personalized, efficient, and accessible care for AD patients worldwide. Continued research, ethical considerations, and regulatory frameworks will be crucial in realizing the full potential of AI in dermatology.

[marcoluther]

How Generative AI is Transforming Healthcare: A Game-Changer for the Industry

The healthcare industry is undergoing a rapid transformation, and one of the most significant drivers of this change is Generative AI. This cutting-edge technology is revolutionizing everything from drug discovery and medical imaging to patient diagnostics and personalized treatment plans. With its ability to analyze vast datasets, recognize patterns, and generate meaningful insights, generative AI is proving to be a game-changer for healthcare professionals, researchers, and patients alike.

In this blog, we’ll explore how generative AI is reshaping healthcare, its key applications, and the potential future impact of this revolutionary technology.

Understanding Generative AI in Healthcare

Generative AI refers to artificial intelligence models that can create new data, such as images, text, or even entire datasets, based on the patterns and knowledge they have learned. These models are powered by deep learning and neural networks, allowing them to perform complex tasks with unprecedented accuracy and efficiency.

In healthcare, generative AI is being used to enhance diagnostics, streamline drug development, and provide personalized medicine. By processing vast amounts of medical data, generative AI can detect anomalies, predict disease progression, and suggest optimal treatment approaches, leading to better patient outcomes and improved healthcare efficiency.

Key Applications of Generative AI in Healthcare

1. Medical Imaging and Diagnostics

Medical imaging plays a crucial role in diagnosing diseases, but interpreting images manually can be time-consuming and prone to human error. Generative AI is revolutionizing radiology and pathology by:

Enhancing the accuracy of X-rays, MRIs, and CT scans

Generating synthetic medical images for training AI models

Detecting early signs of diseases like cancer, Alzheimer’s, and heart conditions

Reducing the need for invasive procedures by providing AI-assisted imaging insights

AI models like Google’s DeepMind and IBM Watson have already demonstrated their ability to outperform human radiologists in detecting anomalies in medical scans.

2. Drug Discovery and Development

Traditional drug discovery is an expensive and time-consuming process, often taking years and billions of dollars to bring a new drug to market. Generative AI is accelerating this process by:

Predicting molecular structures and optimizing drug formulations

Repurposing existing drugs for new diseases

Reducing trial-and-error experimentation in drug research

Generating synthetic data to simulate clinical trials

For example, Insilico Medicine successfully used generative AI to design a novel drug molecule in just 46 days—an achievement that would typically take years.

3. Personalized Medicine and Treatment Plans

Every patient is unique, and their response to treatments can vary significantly. Generative AI enables personalized healthcare solutions by:

Analyzing genomic data to identify the best treatment options

Generating AI-powered treatment plans based on a patient’s medical history

Assisting doctors in making real-time decisions for critical care patients

With AI-driven personalized medicine, doctors can predict how a patient will respond to a specific drug, reducing adverse reactions and improving treatment success rates.

4. Virtual Health Assistants and Chatbots

Generative AI-powered virtual assistants are transforming patient engagement and telemedicine by:

Providing 24/7 virtual consultations for minor ailments

Answering patient queries in real time

Reminding patients to take medications

Assisting doctors with clinical documentation

Companies like Ada Health and Babylon Health have developed AI-driven virtual assistants that help patients self-diagnose symptoms and guide them to appropriate care.

5. Automating Medical Documentation and Administrative Work

Healthcare professionals spend a significant portion of their time on administrative tasks like writing reports, processing claims, and managing medical records. Generative AI streamlines these processes by:

Automating medical transcription and documentation

Generating summaries of patient records

Reducing administrative burden, allowing doctors to focus on patient care

AI tools like Nuance’s Dragon Medical One are already helping healthcare providers automate note-taking, improving efficiency and reducing physician burnout.

6. Predictive Analytics for Disease Prevention

One of the most powerful applications of generative AI is its ability to predict disease outbreaks and patient risks by analyzing data patterns. It can:

Forecast the spread of infectious diseases like COVID-19

Identify individuals at high risk of chronic diseases (e.g., diabetes, cardiovascular conditions)

Suggest preventive measures based on patient history and lifestyle

For instance, BlueDot, an AI-driven health surveillance company, detected the COVID-19 outbreak days before it was officially reported, showcasing AI’s potential in disease prediction.

Challenges and Ethical Considerations

Despite its transformative potential, generative AI in healthcare comes with challenges and ethical concerns, including:

Data Privacy – Ensuring patient data is protected from breaches and misuse

Bias in AI Models – Avoiding biased predictions due to imbalanced training datasets

Regulatory Compliance – Meeting stringent medical regulations and approval processes

Human Oversight – Ensuring AI complements, rather than replaces, human doctors

Addressing these challenges requires transparent AI development, rigorous testing, and collaboration between technology firms, healthcare providers, and regulatory bodies.

The Future of Generative AI in Healthcare

The future of generative AI in healthcare is incredibly promising. With advancements in AI, quantum computing, and biotechnology, we can expect:

Faster drug discovery with AI-designed molecules

More precise and personalized medicine tailored to individual genomes

AI-powered robotic surgeries with enhanced precision

Global AI-driven disease monitoring systems to prevent pandemics

As AI continues to evolve, it will not replace doctors but empower them to deliver better, more efficient, and highly personalized patient care.

Conclusion

Generative AI is redefining healthcare, making it faster, more efficient, and highly personalized. From early disease detection and personalized treatments to virtual health assistants and predictive analytics, AI is a game-changer that is transforming the industry at an unprecedented pace.

While challenges remain, the potential benefits far outweigh the risks. With the right ethical guidelines and responsible AI implementation, generative AI will continue to revolutionize healthcare, improving patient outcomes and shaping the future of medicine.

[btasco]

The Growing Impact of Bioinformatics in Modern Medicine

In the evolving landscape of healthcare, bioinformatics is playing a crucial role in modern medicine. From drug discovery to personalized treatments, this interdisciplinary field bridges biology and computational science to drive medical advancements. Pharmaceutical companies increasingly rely on bioinformatics consulting for pharma to develop innovative therapies, optimize research, and accelerate the drug development process. As medicine becomes more data-driven, the integration of bioinformatics is revolutionizing disease diagnosis, treatment strategies, and overall patient care.

One of the most significant contributions of bioinformatics is in genomic research. With the ability to analyze vast amounts of genetic data, scientists can now identify disease markers, predict genetic disorders, and tailor treatments based on an individual's genetic makeup. This advancement has paved the way for precision medicine, allowing for targeted therapies that improve patient outcomes. Additionally, bioinformatics aids in understanding complex diseases such as cancer, neurological disorders, and infectious diseases by analyzing molecular interactions at an unprecedented scale.

Pharmaceutical companies face immense challenges in drug discovery, including high costs, long development timelines, and the risk of failure. By leveraging bioinformatics, researchers can streamline the process by identifying potential drug candidates, analyzing their effectiveness, and predicting possible side effects before clinical trials. Bioinformatics consulting for pharma provides expertise in data analysis, computational modeling, and algorithm development, making drug development more efficient and cost-effective. The ability to process and interpret biological data rapidly has reduced the time required to bring new treatments to market, benefiting both the industry and patients.

Apart from drug discovery, bioinformatics plays a vital role in vaccine development. With the rise of global health challenges, including pandemics, researchers need tools to quickly identify virus mutations, study immune responses, and design effective vaccines. Bioinformatics enables real-time data analysis, helping scientists stay ahead of emerging diseases and develop targeted vaccines faster than ever before. The COVID-19 pandemic highlighted the power of bioinformatics in accelerating vaccine research, showcasing its importance Role of bioinformatics in modern medicine.

The integration of artificial intelligence (AI) and machine learning with bioinformatics has further enhanced its capabilities. Advanced algorithms can analyze complex biological data, identify patterns, and generate insights that would be impossible through traditional methods. AI-driven bioinformatics tools assist in disease prediction, drug repurposing, and patient-specific treatment recommendations, making healthcare more personalized and efficient.

As bioinformatics continues to transform medicine, companies like btasco.com provide specialized solutions to help pharmaceutical firms navigate this rapidly evolving field. With expert consulting services, researchers can harness the full potential of bioinformatics to develop groundbreaking treatments and improve patient care. The synergy between computational biology and modern healthcare is shaping the future of medicine, ensuring better diagnostics, innovative therapies, and enhanced global health outcomes.

[fgnxfgnfxn]

Unlocking the Future: The Intersection of Artificial Intelligence and Biotechnology

The Rise of Artificial Intelligence in Biotechnology

AI, a branch of computer science focused on creating systems capable of performing tasks that typically require human intelligence, has rapidly infiltrated almost every aspect of modern life. From virtual assistants to self-driving cars, AI is proving itself capable of extraordinary feats. In biotechnology, AI is being applied to solve some of the most complex problems, from genetic analysis to drug discovery, offering unparalleled speed and accuracy.

In Artificial Intelligence in Biotechnology, Artificial Intelligence Biotechnology Book the authors explain how AI technologies, such as machine learning, deep learning, and natural language processing, are already helping researchers and practitioners extract valuable insights from vast amounts of biological data. This shift towards data-driven biotechnology is critical, as the amount of biological information generated today is simply too large for traditional methods to handle effectively. AI algorithms are able to process millions of sequences, patterns, and interactions in ways that humans could never achieve manually.

Revolutionizing Drug Discovery

One of the most exciting applications of AI in biotechnology is drug discovery. The traditional process of developing new medications is notoriously slow and costly, often taking years to complete and costing billions of dollars. AI is transforming this process by analyzing the chemical properties of millions of compounds in a fraction of the time it would take human researchers. With AI, companies can now identify promising drug candidates faster, predict their potential effectiveness, and even foresee possible side effects before entering clinical trials.

Artificial Intelligence in Biotechnology explores several case studies where AI has successfully accelerated the drug discovery process. For instance, the book examines how AI tools were employed in the search for treatments during the COVID-19 pandemic, enabling pharmaceutical companies to sift through vast libraries of existing drugs to find those that could be repurposed for treating the virus. These advancements demonstrate how AI is pushing the boundaries of what is possible in modern medicine.

Personalized Medicine and Genomics

AI’s impact on personalized medicine is another highlight of the book. Personalized medicine tailors treatments to individual patients based on their genetic makeup, Book For AI in Drug Discovery lifestyle, and environment. AI plays a critical role in making this approach feasible, as it allows for the analysis of large genomic datasets and the identification of genetic markers associated with specific diseases.

With AI-driven tools, scientists can now predict how a patient’s genetic makeup will respond to certain treatments, paving the way for more effective and personalized care. The book provides detailed insights into how AI algorithms are being applied to analyze gene sequences and uncover the causes of rare genetic diseases, which were previously difficult to diagnose and treat.

Ethical Considerations and Future Directions

While the benefits of integrating AI into biotechnology are immense, the book also emphasizes the importance of ethical considerations. With AI’s increasing role in decision-making, particularly in healthcare, there are valid concerns regarding data privacy, algorithmic bias, and the potential misuse of biotechnology. The authors of Artificial Intelligence in Biotechnology stress the need for robust ethical frameworks to guide the responsible development and application of AI in this field.

The book also looks forward, discussing the future possibilities of AI in biotechnology. From using AI to tackle climate change through bioengineering to exploring the potential of synthetic biology, the future holds endless possibilities at the intersection of these two fields.

[healthcarehubhh]

Laboratory Informatics: Enabling Digital Transformation of Life Science Research

Laboratory informatics refers to the management of data and information generated during laboratory experiments and research. It involves the use of laboratory information management systems (LIMS), electronic lab notebooks (ELN), scientific data management systems (SDMS), and other software tools to capture, integrate, process, and store laboratory data. Laboratory Informatics Provides Data Integrity and Compliance By automating workflows and processes, lab informatics ensures data integrity and regulatory compliance. Digital records are easier to validate, audit, and protect from alteration compared to paper-based documentation. Electronic data capture eliminates mistakes from manual transcription of test results. Embedded controls and audit trails help demonstrate compliance with guidelines such as GxP, GLP, and data privacy regulations. Improving Workflow Efficiency and Productivity Laboratory informatics streamlines workflows to reduce manual tasks and paperwork. Experiments can be planned, executed, and analyzed using integrated software tools rather than spreadsheets or paper logs. Automated sample processing and result reporting save time otherwise spent on repetitive documentation. Scientists spend less time searching for past data and more time for analysis and discovery. Remote access to systems allows off-site collaboration. Facilitating Data Sharing and Reuse Laboratory informatics makes it easier for scientists to find, access, share, and reuse past data within and across organizations. SDMS stores data in standardized formats alongside metadata like experimental protocols. Search tools enable retrieving relevant data based on parameters. This eliminates the need to repeat experiments and advances scientific knowledge through data-driven research. Integrations with analysis software facilitate repurposing of existing data for new insights. Accelerating Drug Discovery and Translational Research Informatics plays a key role in accelerating drug discovery from target identification to clinical trials. SDMS integrated with analytical instruments capture and link experimental data, chemical structures, biomarkers, and genomic profiles. Applications analyze this extensive biological and chemical data to identify new drug targets and biomarkers. Informatics-driven insights help select the right candidates for further evaluation faster. Integrations with electronic lab notebooks and LIMS support preclinical and clinical research activities. Powering Hypothesis-Driven Research Laboratory informatics fuels hypothesis-driven research by enabling exploration and discovery of patterns in vast amounts of multidisciplinary data. Data mining and analytics tools applied on integrated experimental and outcome datasets help form new research hypotheses. Scientists can ask questions of datasets, quicklyfilterresults, and focus research based on generated insights, rather than searching blindly. Cloud-based platformsmake gigabytes of data remotely accessible for collaborative analysis using simulation models, machine learning and artificial intelligence techniques.

[educationmore]

The Role of Data Science in Healthcare

In recent years, the field of healthcare has witnessed a monumental shift with the integration of data science. As the volume of health-related data continues to grow exponentially, so does the need for skilled professionals who can harness its power. In this blog post, we'll delve into the pivotal role that data science plays in revolutionizing healthcare, exploring how top data science institutes are offering courses with job assistance to meet the industry demand for qualified professionals.

Unraveling the Potential: 

Data Science in Healthcare Healthcare institutions generate vast amounts of data daily, ranging from patient records and diagnostic images to genomic sequences and wearable device metrics. Leveraging this data effectively can lead to improved patient outcomes, enhanced operational efficiency, and groundbreaking medical discoveries. Through advanced analytics and machine learning algorithms, data scientists can extract actionable insights from this wealth of information to drive informed decision-making.

Empowering Precision Medicine: 

One of the most significant advancements facilitated by data science in healthcare is the advent of precision medicine. By analyzing patient data at the individual level, including genetic makeup, lifestyle factors, and treatment history, healthcare providers can tailor interventions to each patient's unique characteristics. This personalized approach holds the promise of more effective treatments with fewer side effects, ushering in a new era of healthcare delivery.

Enhancing Disease Surveillance and Management: 

Data science plays a crucial role in disease surveillance and management, particularly in the context of epidemics and public health emergencies. By analyzing trends in patient data, social media chatter, and environmental factors, epidemiologists can identify potential outbreaks early, allowing for timely intervention and containment measures. Moreover, predictive models powered by data science certification can forecast disease spread and resource allocation, aiding healthcare systems in proactive planning and response.

Optimizing Healthcare Operations: 

Beyond clinical applications, data science also offers immense value in optimizing healthcare operations. From streamlining appointment scheduling and resource allocation to predicting patient admission rates and optimizing inventory management, data-driven insights enable healthcare institutions to operate more efficiently and cost-effectively. By partnering with best data science institutes offering courses with job assistance, healthcare organizations can equip their staff with the skills needed to leverage data for operational excellence.

Driving Medical Research and Innovation: 

The intersection of data science and healthcare fuels a virtuous cycle of innovation and discovery. By analyzing large-scale datasets, such as electronic health records and clinical trial data, researchers can identify patterns, elucidate disease mechanisms, and develop novel therapies. Furthermore, data-driven approaches facilitate the identification of potential drug targets, the optimization of clinical trial protocols, and the repurposing of existing medications, expediting the drug development process and bringing lifesaving treatments to market sooner.

What is Boosting - Machine Learning

Ensuring Data Privacy and Security: 

While the benefits of data science in healthcare are undeniable, safeguarding patient privacy and data security is paramount. Healthcare organizations must adhere to stringent regulations, such as HIPAA in the United States, to protect sensitive patient information from unauthorized access and breaches. Moreover, data scientists must implement robust encryption protocols, access controls, and anonymization techniques to mitigate privacy risks while still extracting meaningful insights from healthcare data.

The integration of data science into healthcare represents a transformative paradigm shift with far-reaching implications. From personalized medicine and disease surveillance to operational optimization and medical research, the applications of data science are vast and varied. By investing in top data science institutes that offer courses with job assistance, healthcare professionals can acquire the skills needed to harness the power of data for improved patient care and outcomes. However, it is imperative that data privacy and security remain paramount to ensure trust and compliance in this data-driven healthcare landscape. As we continue to unlock the full potential of data science in healthcare, the future holds promise for more efficient, effective, and equitable healthcare delivery worldwide.

What is Box Plot - Data Science Terminologies

[primathontechnology]

Advancing Healthcare: The Role of Generative AI Services in Medical Research and Drug Discovery

In the realm of healthcare, medical research and drug discovery are crucial endeavors that drive innovation and pave the way for new treatments and therapies to improve patient outcomes. However, the traditional approach to medical research and drug discovery is often time-consuming, resource-intensive, and prone to challenges such as high failure rates and lengthy development timelines. Artificial Intelligence (AI) is revolutionizing these processes, offering powerful tools and techniques to accelerate discovery, optimize experimentation, and unlock new insights into disease mechanisms and treatment options. Generative AI Services, powered by advanced algorithms and machine learning techniques, are at the forefront of this transformation, enabling researchers and pharmaceutical companies to harness the power of AI to drive innovation and revolutionize healthcare. Let's explore how Generative AI Services are reshaping medical research and drug discovery and driving AI-driven innovation in the healthcare industry.

Empowering Discovery with Generative AI:

Generative AI Services leverage the power of AI-driven algorithms to analyze vast amounts of data, identify patterns, and generate insights that inform medical research and drug discovery efforts. By harnessing Generative AI Services, researchers and pharmaceutical companies can accelerate the discovery process, optimize experimentation, and unlock new opportunities for developing novel treatments and therapies.

1. Predictive Modeling and Simulation:

Generative AI Services enable predictive modeling and simulation by analyzing molecular structures, biological pathways, and disease mechanisms to predict drug interactions, efficacy, and safety profiles. By leveraging machine learning algorithms, Generative AI Services can simulate drug-target interactions, predict compound properties, and prioritize lead candidates for further experimentation, streamlining the drug discovery process and reducing the time and cost associated with traditional approaches.

2. Drug Repurposing and Combination Therapy:

Generative AI Services facilitate drug repurposing and combination therapy approaches by analyzing existing drug data and identifying potential applications for repurposing existing drugs or combining multiple drugs to target complex diseases. By leveraging data analytics and predictive modeling, Generative AI Services can identify synergistic drug combinations, predict treatment responses, and optimize therapeutic regimens, offering new opportunities for accelerating the development of effective treatments for unmet medical needs.

3. Biomarker Discovery and Patient Stratification:

Generative AI Services enable biomarker discovery and patient stratification by analyzing clinical data, genomic information, and molecular profiles to identify biomarkers associated with disease progression, treatment response, and patient outcomes. By leveraging predictive analytics, Generative AI Services can identify predictive biomarkers, stratify patient populations, and personalize treatment approaches, facilitating precision medicine strategies and improving patient outcomes in clinical trials and clinical practice.

4. Target Identification and Validation:

Generative AI Services support target identification and validation efforts by analyzing genomic data, protein structures, and disease pathways to identify potential drug targets and validate their relevance in disease pathogenesis. By leveraging machine learning algorithms, Generative AI Services can prioritize target candidates, predict their druggability, and validate their therapeutic potential, guiding drug discovery efforts and accelerating the development of novel treatments for various diseases.

5. Real-time Data Analysis and Decision Support:

Generative AI Services offer real-time data analysis and decision support by analyzing streaming data from clinical trials, electronic health records, and patient monitoring devices to identify trends, detect anomalies, and optimize trial design and patient recruitment strategies. By leveraging predictive analytics and data visualization techniques, Generative AI Services can provide researchers and clinicians with actionable insights, facilitating data-driven decision-making and improving the efficiency and effectiveness of medical research and drug discovery processes.

Conclusion:

In conclusion, Generative AI Services are revolutionizing medical research and drug discovery, enabling researchers and pharmaceutical companies to accelerate discovery, optimize experimentation, and unlock new insights into disease mechanisms and treatment options. By leveraging advanced algorithms and machine learning techniques, Generative AI Services offer a comprehensive suite of capabilities to drive innovation and revolutionize healthcare, paving the way for new treatments, therapies, and interventions that improve patient outcomes and transform the healthcare landscape. As the healthcare industry continues to embrace AI-driven innovation and transformative solutions, Generative AI Services will play a pivotal role in shaping the future of medical research and drug discovery, offering new opportunities for advancing healthcare and improving lives around the world.

[aissmseducation]

Drug Repurposing Using Artificial Intelligence

Author-

Indrani Raman Mahadik

Second Year M. Pharm(Chemistry)

How machine learning can be used to find new therapeutic uses for already-approved medications, potentially cutting down on the time and expense of drug development.

The process of discovering new therapeutic uses for existing drugs that have already been approved for a different indication is known as drug repurposing. Because of its potential to reduce the time and costs associated with drug development, this approach has gained popularity in recent years. In this blog post, we will look at how machine learning can be used to discover new therapeutic applications for existing drugs.

One approach to drug repurposing using machine learning is to use computational models to predict the efficacy of existing drugs in treating various diseases. A machine learning algorithm, for example, can be trained on a dataset of gene expression data from patients with a specific disease, as well as information about the drugs used to treat that disease. Based on known mechanisms of action and observed gene expression patterns, the algorithm can then use this data to identify drugs that are likely to be effective in treating the disease.

Another approach to drug repurposing with machine learning is to identify new drug-disease associations using network-based methods. Drugs and diseases are represented as nodes in a network in this approach, with edges representing known interactions between them. Machine learning algorithms can then be used to identify novel drug-disease associations based on the network structure and node properties.

By analysing large amounts of data and identifying potential new therapeutic uses for existing drugs, machine learning, a subset of artificial intelligence, can play a critical role in drug repurposing. Here are some examples of how machine learning can be applied to drug repurposing:

Identifying subtypes of diseases: Based on clinical and molecular characteristics, subtypes of diseases can be identified with machine learning. This can assist in locating currently available medications that might be useful for treating a specific subtype of a disease.

Bringing together data from various sources: Integrating data from a variety of sources, including clinical trial data, genomics data, and electronic health records, is one way that machine learning can find new therapeutic applications for existing drugs.

Putting drug candidates first: Prioritize existing drugs based on their potential for repurposing with machine learning. This can assist researchers in concentrating on drugs that are most likely to treat a specific disease.

New clinical trial design: New clinical trials for repurposed drugs can be designed with the help of machine learning. These algorithms can assist in determining the most promising repurposed drugs for clinical trials by analyzing data on patient characteristics and disease subtypes.

Recent instances of AI-enabled drug repurposing successes

A number of recent studies have demonstrated machine learning’s potential for drug repurposing. A machine learning algorithm was used in a 2020 Nature Communications study to predict the therapeutic potential of 1,309 FDA-approved drugs for 55 different cancers. The antipsychotic drug thioridazine, which was found to be effective against acute myeloid leukemia, was one of several drugs that the algorithm identified that showed promise for treating particular types of cancer.

Another example is a study that used machine learning to find potential drugs that could treat COVID-19 and was published in Nature Biotechnology in 2021. A neural network algorithm was used by the researchers to analyze the molecular structures of existing drugs and predict their capacity to bind to the SARS-CoV-2 spike protein, a vital virus component. The algorithm found several drugs that could treat COVID-19, including the antidepressant fluvoxamine and the antiparasitic niclosamide.

To summarise, machine learning has the potential to transform drug repurposing by identifying novel therapeutic uses for existing pharmaceuticals in a more efficient and cost-effective manner. However, the quality of the data used to train the algorithms must be carefully monitored, and the findings must be interpreted with sensitivity to ensure that they are biologically meaningful.

[drugdiscoveryalliances]

Revolutionizing Pharmaceuticals Innovations Transforming Pharma Companies

In the fast-paced world of healthcare, pharmaceutical companies are continuously evolving to meet the ever-growing demands of patients, healthcare providers, and regulatory authorities. Innovation has become the cornerstone of success for these companies, driving breakthroughs in drug discovery, manufacturing, and patient care. In this article, we delve into the transformative innovations that are reshaping the pharmaceutical industry.

1. Artificial Intelligence and Machine Learning:

One of the most significant advancements in pharmaceuticals is the integration of artificial intelligence (AI) and machine learning (ML) into drug discovery and development processes. These technologies can analyze vast datasets and identify potential drug candidates, predict patient responses, and optimize clinical trial designs. By significantly reducing the time and cost of drug development, AI and ML are paving the way for more efficient and personalized treatments.

2. Biotechnology and Gene Therapy:

The rise of biotechnology and gene therapy has led to the development of revolutionary treatments for previously untreatable diseases. Companies are harnessing the power of CRISPR-Cas9 and other gene-editing tools to target and correct genetic mutations responsible for inherited disorders. This transformative approach has the potential to cure diseases at their root, offering hope to patients and creating new avenues for business growth.

3. Personalized Medicine:

Pharma companies are shifting towards a personalized medicine approach. Rather than adopting a one-size-fits-all model, they are tailoring treatments to individual patient profiles. This approach, driven by advancements in genomics and biomarker identification, not only improves patient outcomes but also streamlines drug development by focusing on specific patient populations.

4. Continuous Manufacturing:

Traditional pharmaceutical manufacturing processes have been characterized by batch production, which can be slow and costly. Continuous manufacturing is changing this paradigm by allowing the uninterrupted production of medications. This innovation enhances product quality, reduces waste, and shortens production timelines, ultimately benefitting both manufacturers and patients.

5. Telemedicine and Digital Health:

The COVID-19 pandemic accelerated the adoption of telemedicine and digital health solutions. Pharma companies are increasingly partnering with tech companies to develop and market digital therapeutics, remote monitoring devices, and patient engagement platforms. These innovations improve patient adherence, enhance data collection for clinical trials, and expand market reach.

6. Drug Repurposing:

In the quest to bring new drugs to market, pharmaceutical companies are also reevaluating existing medications for new therapeutic uses. Drug repurposing leverages the wealth of data available to identify potential off-label uses for existing drugs. This approach can significantly reduce development timelines and costs while providing novel treatment options.

7. Regulatory Reforms:

Innovation isn't limited to science and technology; it also extends to regulatory processes. Governments and regulatory authorities are adopting more flexible approaches to accommodate the rapid pace of pharmaceutical innovation. Expedited approval pathways and regulatory frameworks that support breakthrough therapies are becoming more common, encouraging companies to take risks in their research and development endeavors.

8. Sustainability Initiatives:

Pharmaceutical companies are also focusing on sustainability, recognizing their role in environmental conservation. They are implementing green manufacturing practices, reducing waste, and developing eco-friendly packaging solutions. Sustainability not only aligns with corporate social responsibility but also attracts environmentally conscious consumers.

the pharmaceutical industry is undergoing a profound transformation driven by technological advancements, patient-centric approaches, and a commitment to sustainability. These innovations are reshaping how drugs are discovered, developed, manufactured, and delivered to patients, ultimately improving healthcare outcomes and the industry's overall efficiency. As pharmaceutical companies continue to embrace innovation, the future holds promise for groundbreaking discoveries and a healthier world.

For More Info:-

Innovating Pharma Companies

learn more

click here

[clinical01]

Rare Diseases Research: Bridging the Gap in Treatment Options

In a world driven by advancements in fields like clinical research and software development, one area that often remains underrepresented is rare diseases research. Just as clinical research blogs in Pune highlight the latest updates, this article delves into the critical need for rare diseases research, its challenges, and the role of technology in addressing these challenges.

Understanding Rare Diseases:

Clinical Research Blogs Parallels: Just as clinical research companies disseminate information, rare diseases research aims to raise awareness about lesser-known conditions.

Neglected Conditions: Similar to the way clinical research in Pune emphasizes lesser-known topics, rare diseases often lack attention due to their limited prevalence.

Challenges in Rare Diseases Research:

Lack of Information: Similar to clinical research latest updates addressing gaps, rare diseases often lack comprehensive information, making diagnosis and treatment challenging.

Limited Funding: Much like clinical research companies struggle for resources, rare diseases research faces funding constraints.

Small Patient Populations: Similar to the limited readership of clinical research blogs, rare diseases affect a small number of patients, making recruitment for clinical trials difficult.

The Role of Clinical Research in Rare Diseases:

Patient-Centric Approach: Just as clinical research practices prioritize patients, rare diseases research focuses on improving the lives of affected individuals.

Advancements in Diagnostics: Like clinical research companies contribute to diagnostic accuracy, rare diseases research seeks to enhance diagnostic tools for early detection.

Tailored Treatments: Similar to the personalized medicine approach in clinical research, rare diseases research aims to develop targeted therapies.

Technology's Impact:

Data Aggregation: Just as clinical research blogs gather knowledge, technology enables data collection and aggregation to better understand rare diseases.

Virtual Collaboration: Similar to the virtual collaboration seen in clinical research, technology connects researchers globally for sharing insights.

Genomic Sequencing: Like the genomic advancements in clinical research, genomic sequencing aids in understanding the genetic basis of rare diseases.

Software Development Updates for Rare Diseases:

Customized Solutions: Similar to the customization seen in software development updates, developing specialized tools for rare diseases aids in diagnosis and research.

Patient Databases: Much like clinical research companies maintain databases, software tools can help create patient registries for rare diseases research.

Clinical Research Latest Updates for Rare Diseases:

Shared Knowledge: Just as clinical research blogs share insights, latest updates in rare diseases research contribute to a collective understanding of these conditions.

Treatment Discoveries: Similar to clinical research companies making breakthroughs, the latest updates in rare diseases research lead to innovative treatment approaches.

Promising Approaches in Rare Diseases Research:

Repurposing Existing Drugs: Similar to the way clinical research practices repurpose drugs for new indications, existing medications can offer hope for rare diseases.

Gene Therapy: Much like the gene-based advancements in clinical research, gene therapy shows promise in treating certain rare genetic conditions.

Collaboration for Solutions:

Parallel with Clinical Research: Just as clinical research emphasizes collaboration, rare diseases research requires cooperation among researchers, patients, and organizations.

Multi-Disciplinary Approach: Similar to the multi-disciplinary nature of clinical research, rare diseases research involves diverse expertise.

Advocacy and Awareness:

Similar to Clinical Research Blogs: Just as clinical research blogs raise awareness, advocacy groups play a crucial role in spreading knowledge about rare diseases.

Fighting Stigma: Like clinical research companies combat stigmatization, raising awareness reduces the stigma associated with rare diseases.

Patient-Centered Care:

Analogous to Clinical Research: Just as clinical research prioritizes patient welfare, rare diseases research focuses on improving the lives of those affected.

Empowering Patients: Similar to the empowerment seen in clinical research, rare diseases research empowers patients to be active participants in their care.

Future Possibilities:

Similar to Clinical Research Advances: Just as clinical research evolves, rare diseases research holds the potential for groundbreaking discoveries and improved treatments.

Precision Medicine: Much like the personalized approach in clinical research, precision medicine can transform rare diseases treatment.

Conclusion:

The connection between rare diseases research and clinical research blogs in Pune lies in their shared objective of expanding knowledge and improving lives. Just as clinical research companies contribute to medical advancements, rare diseases research aims to bridge treatment gaps for those often overlooked. Despite challenges, technology and collaborative efforts pave the way for innovative solutions. Like clinical research practices bring hope to patients, rare diseases research seeks to provide treatments and hope to those facing unique health struggles. It is the collective dedication of researchers, patients, and advocates that will ultimately lead to a brighter future for individuals affected by rare diseases.

[didanawisgi]

“If you've ever seen a petunia with artfully variegated petals, then you've seen transposons at work. The flower's showy color patterns are due to transposable elements, or DNA sequences that can move locations within a genome. Yet when it comes to transposons' effects on humans, the results might not be as lovely or desirable.

As researchers learn more about these so-called mobile genetic elements, they've found increasing evidence that transposons influence and even promote aging and age-related diseases like cancer as well as neurogenerative and autoimmune disorders, says John Sedivy, a professor of biology and director of the Center on the Biology of Aging at Brown. Sedivy is the corresponding author of a new review article in Nature that discusses the latest thinking and research around transposons.

"Let's put it this way: These things can be pretty dangerous," said Sedivy. "If they are uncontrolled, and there are many examples of that, transposons can have profound consequences on most forms of life that we know of."

Since the dawn of life, the researchers noted, transposons have coevolved with their host genomes, but it's been more of a competitive existence than a peaceful one, earning them the nicknames of "junk DNA" and "molecular parasites." Transposons were first discovered in corn by the Nobel prize-winning geneticist Barbara McClintock in the 1940s, who also found that depending on where they inserted into a chromosome, they could reversibly alter the expression of other genes.

It is now quite apparent that the genomes of virtually all organisms, including humans, contain repetitive sequences generated by the activity of transposons. When these elements move from one chromosome or part of a chromosome to another, they amplify and increase their presence in genomes, sometimes to dramatic levels. According to Sedivy, "about half of the human genome is due to the activity of these molecular parasites." Their unregulated activity can have long-term benefits by increasing genetic diversity in organisms, but in most cases the chaos degrades cell function, such as by disrupting useful genes.

Most of what is known about transposons, said Sedivy, comes from genome sequence data that shows their activity in the germline, or throughout successive generations of an organism. However, recent research, including from Sedivy and other scientists at Brown, has revealed a wealth of information on transposon activity during the lifetime of a single individual, as well.

In an interview, Sedivy discussed the mechanisms driving transposons, how their activity influences and promotes age-related tissue degeneration and disease—and what can be done to fight back.

Q. Transposons are mobile genetic elements. How and why do they move?

There are two main groups: 'DNA transposons' move using a DNA intermediate in a 'cut and paste' mechanism, and retrotransposons move using a 'copy and paste' mechanism that involves an RNA intermediate. Thirty five percent of the human genome is comprised of retrotransposon DNA sequences. The reason they move is to survive; it allows them to relocate to and increase their presence in their hosts. You can think of transposons as viruses —there are some viruses that are, in fact, transposable elements. HIV (human immunodeficiency virus) is a perfect example because it uses the retrotransposition mechanism to insert itself into the genome, and then lets the host cell do the replication for it. This means that unless you kill all the cells that HIV has infected, you can't get rid of it. That's what retrotransposons do, too. They live in the genome, including the germline so that eggs and sperm carry these genetic elements and pass them along to future generations.

Q. Scientists have known about these rogue genetic elements for awhile, but transposons are an increasingly important area of study. You are the principal investigator of a collaborative project funded by the National Institutes of Health to examine retrotransposon activity. In addition, the NIH has recently issued a call for grant applications to further explore how this activity contributes to aging and Alzheimer's. What caused this renewal in interest?

Transposons have been studied quite extensively, one important impact in medicine being their role in propagating antibiotic-resistance genes in bacteria. The level of activity in an individual human body, over a single lifetime, was thought to be quite low and of minimal consequence. It's now become quite obvious that's not the full story.

Q. What role to transposons play in the aging process?

First of all, it's important to realize that aging is not an active process. While it might seem that you're programmed to deteriorate, aging is in fact a successive sequence of failures. Cellular processes and mechanisms become more error-prone over time. Cancer, for example, is a disease of aging because at some point, a fatal error is committed which then propagates and leads to disease. As biologists who study aging, we applied the error and failure theory to retrotransposable elements – and discovered that's exactly what was happening. It's now widely appreciated that over a lifespan, these elements become more active in somatic tissues—there's very good evidence that this is happening. There are multiple surveillance mechanisms that our cells use to keep these elements under control and suppress their activity; several layers of active defense that are necessary to keep the retrotransposons under wraps, so to speak. It appears that aging, or senescent, cells lose some of their ability to control the activity of retrotransposons. The defense mechanisms no longer work as well.

Q. What is the connection between retrotransposons and Alzheimer's?

The aging brain of a person with Alzheimer's already shows a significant amount of damage. There's also reasonably good evidence that the brain, for some reason, is a particularly permissive site for retrotransposon activity, so the retrotransposons can basically have a field day in that tissue because there's very little that can stop them. So they promote further damage. This is a major topic in our recent review article in Nature. The question becomes: What can be done to limit the activity of these elements?

Q. What has your research shown about pharmaceutical interventions for retrotransposon activity in the brain?

The first class of HIV/AIDS drugs, called reverse transcriptase inhibitors, are effective against retrotransposons in humans. As I mentioned earlier, HIV is actually a retrotransposon. The key enzyme that HIV uses to replicate, its reverse transcriptase, is the same enzyme that all other retrotransposons use—it's an integral part of their life cycle. Now, even though these enzymes are evolutionarily related, that doesn't necessarily mean that a drug against one will work against the other. But we discovered that a small subset of HIV/AIDS reverse transcriptase inhibitors are actually quite effective against an important class of retrotransposons called LINE-1. In a paper published in 2019 in Nature, we found that the generic HIV drug lamivudine significantly reduced age-related inflammation and other signs of aging in mice. The next step would be to look at the effects in humans.

Q. Can you talk about the Alzheimer's clinical trial you are working on with Dr. Stephen Salloway, associate director for the Brown Center for Alzheimer's Disease Research?

I work on the basic science side, looking at the cellular and molecular processes, and Stephen Salloway is working on the clinical side, testing interventions with patients. We are currently involved in a randomized, double-blind clinical trial to test the effects of a daily oral dose of an HIV retroviral drug on participants with mild dementia due to Alzheimer's disease. The drug, emtricitabine, is also a reverse transcriptase inhibitor—it's a newer generation of the same class of drugs as lamivudine, and shows better tolerability and fewer side effects in humans. Because this is a repurposing trial—using a drug for a purpose other than what it's been prescribed for—the first thing that needs to be addressed is safety. This drug is approved and is currently being used to treat HIV/AIDS in millions of people, but safety and tolerability need to be tested in a geriatric population with mild dementia due to Alzheimer's disease. That's the primary objective of this trial, which we'll be starting at Butler Hospital very soon.

Q. In which other diseases or conditions can retrotransposons be implicated?

The body's immune system recognizes retrotransposons as viruses and mounts an immune response. This immune response is inappropriate, given that retrotransposons are part of our genomes, and there is good evidence that retrotransposons are linked to autoimmune diseases. A pro-inflammatory role of retrotransposons has been noted in rheumatoid arthritis, systemic lupus, erythematosus (SLE) and Sjogren's syndrome.

Q. Where is the research headed?

As we noted in the review article, much work remains to be done on the basic biology side to understand the mechanisms and consequences of retrotransposon activation in people. We also made the point that there is also a need for a more holistic view of how aging mechanisms contribute to disease—and vice versa. We know a fair amount about retrotransposon activation in senescent cells, but much less about the extent and mechanism of activation in most of the mature cells in our bodies, such as neurons or myocytes. As for potential therapy, nucleoside reverse transcriptase inhibitors have shown early promise, and there is hope that these can be repurposed for Alzheimer's and dementia as well as other conditions. It's an exciting time to be working in this field.

More information: Vera Gorbunova et al, The role of retrotransposable elements in ageing and age-associated diseases,Nature (2021).  DOI: 10.1038/s41586-021-03542-y Journal information: Nature

[fgnxfgnfxn]

Artificial Intelligence in the Biological Sciences: Revolutionizing Research and Discovery

AI in Genomics: Accelerating DNA Analysis

One of the most significant impacts of AI in biological sciences is in genomics, where it is helping to decode the complexities of the human genome. Sequencing an organism's DNA generates enormous amounts of data, which require complex analyses to draw meaningful conclusions. AI algorithms, particularly those in machine learning (ML) and deep learning, can process this data quickly and efficiently.

For example, AI models are now being used to identify genetic mutations associated with diseases, predict the functional consequences of these mutations, and even model the likely evolutionary pathways of certain genes. In human health, this can translate into better understanding of genetic diseases, improved diagnostics, and the identification of personalized treatment options based on an individual's unique genetic makeup.

AI has also been instrumental in genome editing technologies such as CRISPR. By analyzing large datasets, AI helps improve the accuracy of gene editing techniques, reducing off-target effects and ensuring precise modifications. Artificial Intelligence in The Biological Science These advancements have significant implications for agriculture, medicine, and evolutionary biology.

AI in Drug Discovery: Reducing Time and Cost

Traditional drug discovery processes are often long, expensive, and fraught with uncertainty. AI is changing this by accelerating the identification of potential drug candidates and optimizing their development. Machine learning models can sift through databases of known compounds to predict which molecules might interact with specific biological targets. This allows scientists to focus on the most promising candidates for further research, significantly reducing the time and cost involved in drug development.

Pharmaceutical companies have already begun using AI to identify new drugs for diseases such as cancer, Alzheimer’s, and viral infections. By simulating molecular interactions, AI systems can predict how a drug will behave in a biological system, minimizing the need for expensive and time-consuming laboratory tests. Additionally, AI can be used to repurpose existing drugs for new therapeutic applications, a process known as drug repositioning.

AI and Systems Biology: Understanding Complex Biological Networks

AI is also playing a crucial role in systems biology, an interdisciplinary field that seeks to understand complex interactions within biological systems. Traditional approaches to biology often focus on individual components such as genes, proteins, or cells. However, these components do not function in isolation but interact within networks that regulate biological processes.

By applying AI algorithms, researchers can model these networks to understand how different biological systems behave in health and disease. For example, AI can analyze gene expression data to identify regulatory networks involved in cancer progression, allowing for more targeted treatments. It can also help in the modeling of metabolic networks, enabling researchers to better understand how organisms respond to environmental changes.

AI and Biophysics: Modeling Protein Structures

Understanding the structure of proteins is critical for many areas of biological research, including drug discovery and disease diagnostics. Proteins are complex molecules that perform a wide range of functions in cells, and their structure determines how they function. However, determining protein structures experimentally is a time-consuming and expensive process.

AI has revolutionized this area with models like AlphaFold, which can predict protein structures with unprecedented accuracy. Book For AI in Drug Discovery This has opened up new avenues for research into diseases caused by misfolded proteins, such as Alzheimer's, Parkinson’s, and Huntington's disease. By understanding how proteins fold and function, researchers can develop more effective therapies.

Future Prospects: AI and Synthetic Biology

Looking forward, the integration of AI into synthetic biology holds exciting prospects. Synthetic biology involves designing and constructing new biological systems or modifying existing ones for useful purposes, such as producing biofuels, developing new materials, or engineering cells to produce therapeutic compounds. AI can assist in the design and optimization of synthetic biological systems, making the process more efficient and predictable.

[ayurvedainitiative-blog]

A collaborative research study by DAILAB @ IIT Delhi and DAILAB @ AIST (National Institute of Advanced Industrial Science and Technology), Japan has recently discovered that Ashwagandha may hold an efficient anti-COVID-19 drugA novel strain of coronavirus (SARS-CoV-2) that emerged in Wuhan city, China in December 2019 has caused pneumonia outbreak in more than 150 countries called COVID-19. As of May 17, 2020, it has infected around 45,25,497 individuals globally with 3,07,395 deaths, as reported by WHO in its COVID-19 Situation Report - 118.The outbreak, declared as a Global health emergency on January 30, 2020, disrupted normal life to the extent of calling world almost to a halt. Though some treatment options including the use of Remdesivir, Hydroxychloroquine, Lopinavir, Ritonavir, APN01 or Favilavir are being tested in clinical trials across the globe, yet no effective therapy has been announced. While new line of drug and vaccine development have been initiated world-wide, in the current scenario of high infected numbers, severity of the disease and high morbidity, repurposing of the existing drugs are heavily explored by recruiting integrative genomics and bioinformatics research tools.SARS-CoV-2 virus genome and structure have been recently published triggering drug designing, devising and development using informatics and experimental tools, worldwide. DAILAB (DBT-AIST International Laboratory for Advanced Biomedicine) teams @IIT Delhi and @AIST Japan, working on natural compounds from Ashwagandha and propolis for last several years, explored the possibility of some of their bio-actives to interact with SARS-CoV-2.In a research paper, just accepted for publication in the J Biomol Struct Dyn, the team has reported that natural compounds from Ashwagandha and propolis have the potential to be effective anti-COVID-19 drug candidates. The researchers targeted the main SARS-CoV-2’s enzyme for splitting proteins, known as the Main protease or Mpro that plays a key role in mediating viral replication. This is an attractive drug target for this virus, and as humans don’t naturally have this enzyme, compounds that target Mpro are likely to have low toxicity. They discovered that Withanone (Wi-N), a natural compound derived from Ashwagandha (Withania somnifera) and Caffeic Acid Phenethyl Ester (CAPE), an active ingredient of New Zealand propolis, have the potential to interact with and block the activity of Mpro. The team described that they have also searched for the capability to these bioactives to modulate the protein on the surface of human cells, to which the SARS-CoV-2 binds and allows its entry into our cell - the transmembrane protease serine 2 (TMPRSS2), and selected Withanone. The study is currently under review and expected to be published in a near future.The team said that their findings may not only connect to save time and cost required for screening for anti-COVID-19 drugs, but may also offer some preventive and therapeutic value for the management of fatal COVID-19 pandemic, and hence warrant prioritized validation in the laboratory and clinical tests. They added that the drug development may take a while and in the current scenario, these natural resources (Ashwagandha and Propolis) may offer some preventive or even therapeutic value. However, although they are easily available and affordable, one has to be cautious about the content of bioactive ingredients. CAPE, while is a major component of propolis, its amount and stability are critical factors that could be managed by generating its complex with cyclodextrins. This has been earlier described by the DAILAB team. Withanone, on the other hand, varies with geography/parts/size of the Ashwagandha plant. So, in order to acquire or appreciate particular effects, we must use the right and quality-controlled resource/extracts.Prof. D. Sundar, Coordinator of DAILAB @ IIT Delhi & Head of the Department of Biochemical Engineering and Biotechnology at IIT Delhi said, “The traditional medicine system ‘Ayurveda’ has been practiced for thousands of years in India. Unlike modern medicine, the mechanism of action of natural drugs has not been resolved so far. IIT Delhi and AIST researchers have been working together for more than a decade and trying to contribute to strengthen this avenue by merging the traditional knowledge with the modern technologies.”He added, “While well-trusted reputation of Ashwagandha as an immunity enhancer forms a basis of the recent initiative of the Indian Government in forming an Interdisciplinary Task Force [joint initiative of Ministry of AYUSH, Ministry of Health and Family Welfare (MoHFW), the Ministry of Science & Technology through Council of Scientific & Industrial Research (CSIR) with Indian Council of Medical Research (ICMR)] to launch its clinical research studies related to SARS-CoV-2 and the COVID-19 disease, the current research report of this team provide hints on its direct anti-viral activities.”The other authors on this paper were Vipul Kumar (PhD student, IIT Delhi) and Jaspreet Kaur Dhanjal (PhD alumni from IIT Delhi and currently a post-doctoral fellow at AIST).Prof. Sundar said that they could not accomplish these findings without the effective collaborations with Dr. Renu Wadhwa (Prime Senior Research Scientist and Head of AIST-INDIA DAILAB) and Dr. Sunil Kaul (Senior Research Scientist, AIST-INDIA DAILAB) of National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, Japan.

[thomasbrutnell]

With over two decades of experience in the fields of plant genomics and developmental biology, Dr. Thomas Brutnell serves as the vice president of Gateway Biotechnology in St. Louis, Missouri. In this role, Dr. Thomas Brutnell oversees the product development of repurposed FDA-approved drugs and new drug candidates to prevent and treat noise-induced hearing loss.